Rss

Archives for : Cancer

How Oncotarget is Improving Medical Research

Oncotarget is one of the most successful open access journals in the world. The journal was introduced into the market in the year 2010, and it is published once a week. Since its introduction into the research world, the journal has been so successful, and it has assisted people to acquire the knowledge they want to become experts in various fields. The journal mostly focuses on oncology topics, and this is one of the reasons it has gained so much popularity in the recent times. The main mission of the journal is to ensure that people can get the knowledge they fast.Due to the quality of content published in the journal, several platforms have named it as one of the best in the industry. A recent study indicates that the average impact factor of the scientific journal is 5.0 in the recent years. The study shows that the success of the journal has been attributed to the kind of professionalism and expertise the editors have been portraying.

The members of the editorial board are also experts who work day and night to make sure that the audience only gets the best news.Mikhail Blagosklonny, a prominent figure in the oncology world is currently the chief editor of the scientific journal. With the assistance of another chief editor, known as Andrei Gudkov, Mikhail has played a leading role in the success of the journal. Having spent many years in the oncology world, the businessman understands the industry very well, and he has all the expertise needed to lead the journal. One of his greatest achievements in the introduction of a drug known as rapamycin to cure cancer and at the same time reduce aging.

The drug is already being used in the market, and experts say that it has generated very positive results. Mikhail currently serves as the professor of Oncology at the Roswell Park Institute.The editorial board at Oncotarget is a team of respected researchers and scholars who have proven to be experts in different sections. These individuals must receive numerous accolades to prove that they are capable of handling the information that is posted in the journal. Under the leadership of Mikhail, the editorial board has published some of the most sensitive topics in the scientific world. One of the studies posted by Oncotarget is the use of electronic cigars in the modern times. The journal says that the cigars are very harmful to the users.

Eric Lefkofksy anticipates human genome sequencing will drive medical developments

Eric Lefkofsky is indisputably one of the most talented entrepreneurs in America. Having founded Groupon, a company that allows individuals to enjoy volume discounts on products and services they need, he has gone on to have a superlative career, starting half a dozen highly successful companies. Today, Lefkofsky has taken on a new challenge, radically overhauling the way in which cancer is treated.

The most important task of artificial intelligence

Lefkofsky’s wife was diagnosed with advanced stage breast cancer in 2013. Throughout the rest of that year, he spent a great deal of time taking her to oncology appointments. Throughout this period, Lefkofksy was struck by how seemingly primitive the means oncologists used to gather and analyse information was. He decided that oncology needed a boost in the way it collates and presents data to its practitioners.

In 2016, Eric Lefkofsky founded Tempus, a company dedicated to collected vast amounts of data and presenting it in a user-friendly, digestible way to oncologists. Today, Lefkofsky sees an even bigger prize. The human genome itself is a trove of potentially ground-breaking information so vast that there currently does not exist a system of mining it. What Tempus seeks to do is to create a system that can use the entire human genome as a blueprint to design the most effective possible cancer treatments. Lefkofksy envisions this as eventually giving oncologists such as nuanced ability to create treatment regimens that every single cancer patient will have their own treatments designed specifically for them, right down to the molecules used in the drugs.

And if this all sounds a bit like science fiction, Lefkofsky is quick to point out that the majority of technological capability to do these things is already here. It just requires a little more tweaking and a specialty application, which is what Tempus is creating, to get that information into the hands of oncologists.

Lefkofsky believes that these innovations will lead to dramatic improvements in survivability of many types of cancer over the next decade. He thinks it is possible that, like with AIDS, cancer may one day soon have treatments that are so good that they are tantamount to a cure.

To know more visit @: norcal.news/news/23733-eric-lefkofsky-searches-coast-coast-cure